Cargando…
Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their clinical benefit to more patients, a novel therapy to induce positive conversion in T790M-negative patients may be possible. We retrospective...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205165/ https://www.ncbi.nlm.nih.gov/pubmed/30410675 http://dx.doi.org/10.18632/oncotarget.26192 |